Suppr超能文献

孕激素受体快速信号传导介导丝氨酸345磷酸化并与特异性蛋白1转录因子结合。

Progesterone receptor rapid signaling mediates serine 345 phosphorylation and tethering to specificity protein 1 transcription factors.

作者信息

Faivre Emily J, Daniel Andrea R, Hillard Christopher J, Lange Carol A

机构信息

Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA.

出版信息

Mol Endocrinol. 2008 Apr;22(4):823-37. doi: 10.1210/me.2007-0437. Epub 2008 Jan 17.

Abstract

Human progesterone receptors (PR) rapidly activate cytosolic signaling pathways, in addition to their classical function as ligand-activated transcription factors. Using ER+/PR-B+ T47D breast cancer cells, we probed the role of progestin-stimulated rapid PR signaling in the transcriptional regulation of target genes involved in breast cancer cell proliferation. Epidermal growth factor receptor (EGFR) was rapidly activated after a 10-min treatment with R5020. Progestin induced EGFR-, c-Src-, and MAPK-dependent phosphorylation of PR-B on the MAPK consensus site, Ser345. Ser345-phosphorylated PR-B receptors strongly associated with specificity protein 1 (Sp1) transcription factors to regulate PR cell cycle (p21) and growth-promoting (EGFR) target genes whose promoters lack canonical progesterone response element sequences. Inhibitors of EGFR, c-Src, or MAPK activities blocked PR tethering to Sp1 and progestin-stimulated S-phase entry. Mutant PR-B receptors defective for c-Src binding (mPro) were not phosphorylated on Ser345 in response to progestin and failed to interact with Sp1. Hormone-induced complexes containing Sp1 and wild-type PR-B, but not S345A or mPro PR-B, were recruited to Sp1 sites within the endogenous p21 promoter. Progestin-induced S-phase entry was attenuated in T47D cells containing wild-type PR-B and treated with EGFR, c-Src, or MAPK kinase inhibitors or in T47D cells stably expressing mPro or mutant DNA-binding domain PR-B. In sum, rapid progestin-activated PR signaling leads to PR Ser345 phosphorylation and tethering to Sp1. These events are critical for progestin-stimulated regulation of Sp1 target genes and breast cancer cell proliferation. Our data demonstrate the therapeutic potential for PR-targeted breast cancer treatment by exploiting multiple nodes along the PR signaling pathway, including PR-B, EGFR, c-Src, MAPK, or Sp1.

摘要

人类孕酮受体(PR)除了作为配体激活的转录因子具有经典功能外,还能快速激活细胞溶质信号通路。我们使用雌激素受体阳性/孕酮受体B亚型阳性(ER+/PR-B+)的T47D乳腺癌细胞,探究了孕激素刺激的PR快速信号传导在参与乳腺癌细胞增殖的靶基因转录调控中的作用。用R5020处理10分钟后,表皮生长因子受体(EGFR)被快速激活。孕激素诱导PR-B在丝裂原活化蛋白激酶(MAPK)的共有位点Ser345发生EGFR、c-Src和MAPK依赖性磷酸化。Ser345磷酸化的PR-B受体与特异性蛋白1(Sp1)转录因子强烈结合,以调控PR细胞周期(p21)和生长促进(EGFR)靶基因,这些靶基因的启动子缺乏典型的孕酮反应元件序列。EGFR、c-Src或MAPK活性抑制剂可阻断PR与Sp1的结合以及孕激素刺激的S期进入。对c-Src结合有缺陷的突变PR-B受体(mPro)在孕激素作用下Ser345未发生磷酸化,且无法与Sp1相互作用。激素诱导的含有Sp1和野生型PR-B的复合物,而非S345A或mPro PR-B,被募集到内源性p21启动子内的Sp1位点。在含有野生型PR-B并经EGFR、c-Src或MAPK激酶抑制剂处理的T47D细胞中,或在稳定表达mPro或突变型DNA结合域PR-B的T47D细胞中,孕激素诱导的S期进入减弱。总之,孕激素快速激活的PR信号传导导致PR的Ser345磷酸化并与Sp1结合。这些事件对于孕激素刺激的Sp1靶基因调控和乳腺癌细胞增殖至关重要。我们的数据表明,通过利用PR信号通路中的多个节点,包括PR-B、EGFR、c-Src、MAPK或Sp1,进行靶向PR的乳腺癌治疗具有治疗潜力。

相似文献

3
Progesterone receptors induce cell cycle progression via activation of mitogen-activated protein kinases.
Mol Endocrinol. 2005 Feb;19(2):327-39. doi: 10.1210/me.2004-0306. Epub 2004 Oct 14.
7
Progesterone receptor inhibits proliferation of human breast cancer cells via induction of MAPK phosphatase 1 (MKP-1/DUSP1).
J Biol Chem. 2011 Dec 16;286(50):43091-102. doi: 10.1074/jbc.M111.295865. Epub 2011 Oct 21.
8
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells.
Mol Endocrinol. 2014 Apr;28(4):442-57. doi: 10.1210/me.2013-1196. Epub 2014 Feb 25.

引用本文的文献

1
Activation of Genes by Nuclear Receptor/Specificity Protein (Sp) Interactions in Cancer.
Cancers (Basel). 2025 Jan 17;17(2):284. doi: 10.3390/cancers17020284.
2
Hormone Signaling in Breast Development and Cancer.
Adv Exp Med Biol. 2025;1464:279-307. doi: 10.1007/978-3-031-70875-6_15.
3
Insulin-like growth factor binding protein-6 modulates proliferative antagonism in response to progesterone in breast cancer.
Front Endocrinol (Lausanne). 2024 Dec 4;15:1450648. doi: 10.3389/fendo.2024.1450648. eCollection 2024.
5
Progesterone-mediated remodeling of the maternal-fetal interface by a PGRMC1-dependent mechanism.
J Reprod Immunol. 2024 Jun;163:104244. doi: 10.1016/j.jri.2024.104244. Epub 2024 Mar 21.
6
Progesterone signaling in the regulation of luteal steroidogenesis.
Mol Hum Reprod. 2023 Jul 31;29(8). doi: 10.1093/molehr/gaad022.
7
Progesterone Receptor Gene Polymorphisms and Breast Cancer Risk.
Endocrinology. 2023 Feb 11;164(4). doi: 10.1210/endocr/bqad020.
8
DGMP: Identifying Cancer Driver Genes by Jointing DGCN and MLP from Multi-omics Genomic Data.
Genomics Proteomics Bioinformatics. 2022 Oct;20(5):928-938. doi: 10.1016/j.gpb.2022.11.004. Epub 2022 Dec 1.
9
Rapid Actions of the Nuclear Progesterone Receptor through cSrc in Cancer.
Cells. 2022 Jun 18;11(12):1964. doi: 10.3390/cells11121964.
10
The Role of Progesterone Receptors in Breast Cancer.
Drug Des Devel Ther. 2022 Jan 26;16:305-314. doi: 10.2147/DDDT.S336643. eCollection 2022.

本文引用的文献

1
Phosphorylation-dependent antagonism of sumoylation derepresses progesterone receptor action in breast cancer cells.
Mol Endocrinol. 2007 Dec;21(12):2890-906. doi: 10.1210/me.2007-0248. Epub 2007 Aug 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验